HCT is frequently offered as a curative option for children with benign and malignant conditions. Improvements in HCT strategies have increased survival by approximately 10% per decade. In fact, long-term survival is an expected outcome for many children and adolescents who undergo HCT. The growing population of long-term survivors has brought to the medical forefront a host of chronic and debilitating conditions attributed to toxicity from pre-transplantation exposure, transplantation conditioning regimens, chronic immunosuppression, and GVHD. This presentation provided an overview of health-related outcomes in long-term survivors of childhood HCT, and compared these outcomes to survivors of conventionally treated cancer.
Saro Armenian, DO, MPH
Medical Director, Pediatric Survivorship Clinic, Childhood Cancer Survivorship Program
City of Hope, Los Angeles